Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female between 18 and 75 years of age;~* have a confirmed diagnosis of ulcerative colitis with the extent varying from proctitis to pancolitis;~* currently demonstrating moderately active disease~Exclusion Criteria:~Patients will be excluded from admission to the study if they have/are:~* a history of allergy or hypersensitivity to salicylates or aminosalicylates;~* a history of extensive small bowel resection (\>1/2 the length of the small intestine) causing short bowel syndrome;~* current renal or hepatic disease;~* participated in any drug or device clinical study within 30 days of entry;~* currently enrolled in any other clinical study;~* received any oral, intravenous, intramuscular, or rectally administered corticosteroids within 1 month prior to the Baseline Visit;~* received any other topical rectal therapy during the week prior to the Screening Visit;~* received immunomodulatory therapy including, but not limited to, 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate within 3 months prior to the Baseline Visit;~* received a dose of mesalamine-containing compound by any route from which more than 1.6 g/day of mesalamine was available within 1 week prior to the Screening Visit (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6 g/day of mesalamine);~* received antibiotics, other than topical antibiotics, within 1 week prior to the Screening Visit;~* received aspirin (except for cardioprotective reasons up to a maximum dose of 325 mg/day) or NSAIDs within 1 week prior to the Baseline Visit;~* if female, positive pregnancy test, or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Asacol 2.4 g/day (Type: ACTIVE_COMPARATOR): Asacol (2.4 g/day)
- Asacol 4.8 g/day (Type: EXPERIMENTAL): Asacol (4.8 g/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).